Status:
UNKNOWN
The Role and Mechanism of Vimentin in Sepsis Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
Sepsis is the most common cause of death in the clinical critically ill patients. We have successfully screened the sepsis biomarkers by clinical proteomics approach and found that Vimentin (VIM) play...
Eligibility Criteria
Inclusion
- Sepsis 3.0 was adopted to selected participants
Exclusion
- Participants were excluded if they were younger than 18 years of age; contracted acquired immunodeficiency syndrome; had reduced polymorphonuclear granulocyte counts (\<500 μL-1); died within 24 h after admission to the ICU; refused to participate in the study; or declined treatment during the period of observation.
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03253146
Start Date
July 1 2016
End Date
December 31 2017
Last Update
August 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730